Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?
At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Genomic Health: Launching a Paradigm Shift...and an Innovative New Test case study is a Harvard Business School (HBR) case study written by Stefanos Zenios, Robert Chess, Lyn Denend. The Genomic Health: Launching a Paradigm Shift...and an Innovative New Test (referred as “Genomic Dx” from here on) case study provides evaluation & decision scenario in field of Sales & Marketing. It also touches upon business topics such as - Value proposition, Pricing, Product development, Strategy.
The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.
In late October 2003, Randy Scott and the Genomic Health team had just received the results of Genomic Health's first pivotal trial. The company's product, Oncotype DX, a first-of-its-kind genomic assay that quantified the likelihood of breast cancer recurrence, had exceeded the standard measures of patient age, tumor size, and tumor grade in predicting recurrence outcomes. The study results would be presented at the 2003 San Antonio Breast Cancer Symposium in December and published in the New England Journal of Medicine in December 2004. Scott and his team now faced the challenge of determining how and when to launch this groundbreaking product. The team was eager to get the product to market as quickly as possible. However, extensive market research performed earlier in the year reveals that it had less than 10% awareness in the physician community and even less among consumers. When asked about what factors would influence their adoption, physicians overwhelmingly cited clinical validation studies--and lots of them. Many skeptics within the oncology field felt that the legitimate use of genomics in making treatment decisions was still 10 to 20 years in the future. Finally, Genomic Health still lacked firm commitments from any payers to reimburse Oncotype DX. Explores the decisions the Genomic Health team had to make in defining the marketing plan, pricing, and reimbursement strategies that would give it the greatest chance of success in bringing its new product to market.
| Years | Cash Flow | Net Cash Flow | Cumulative Cash Flow |
Discount Rate @ 6 % |
Discounted Cash Flows |
|---|---|---|---|---|---|
| Year 0 | (10011556) | -10011556 | - | - | |
| Year 1 | 3466516 | -6545040 | 3466516 | 0.9434 | 3270298 |
| Year 2 | 3965423 | -2579617 | 7431939 | 0.89 | 3529212 |
| Year 3 | 3970164 | 1390547 | 11402103 | 0.8396 | 3333426 |
| Year 4 | 3243896 | 4634443 | 14645999 | 0.7921 | 2569469 |
| TOTAL | 14645999 | 12702406 |
In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -
Capital Budgeting Approaches
There are four types of capital budgeting techniques that are widely used in the corporate world –
1. Profitability Index
2. Net Present Value
3. Payback Period
4. Internal Rate of Return
Apart from the Payback period method which is an additive method, rest of the methods are based on
Discounted Cash Flow
technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.
Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –
1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Genomic Dx shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Genomic Dx have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0
Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate.
Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.
Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project
In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Genomic Dx often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.
To overcome such scenarios managers at Genomic Dx needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.
After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.
| Years | Cash Flow | Net Cash Flow | Cumulative Cash Flow |
Discount Rate @ 15 % |
Discounted Cash Flows |
|---|---|---|---|---|---|
| Year 0 | (10011556) | -10011556 | - | - | |
| Year 1 | 3466516 | -6545040 | 3466516 | 0.8696 | 3014362 |
| Year 2 | 3965423 | -2579617 | 7431939 | 0.7561 | 2998429 |
| Year 3 | 3970164 | 1390547 | 11402103 | 0.6575 | 2610447 |
| Year 4 | 3243896 | 4634443 | 14645999 | 0.5718 | 1854708 |
| TOTAL | 10477947 |
(10477947 - 10011556 )
If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.
| Years | Cash Flow | Net Cash Flow | Cumulative Cash Flow |
Discount Rate @ 20 % |
Discounted Cash Flows |
|---|---|---|---|---|---|
| Year 0 | (10011556) | -10011556 | - | - | |
| Year 1 | 3466516 | -6545040 | 3466516 | 0.8333 | 2888763 |
| Year 2 | 3965423 | -2579617 | 7431939 | 0.6944 | 2753766 |
| Year 3 | 3970164 | 1390547 | 11402103 | 0.5787 | 2297549 |
| Year 4 | 3243896 | 4634443 | 14645999 | 0.4823 | 1564379 |
| TOTAL | 9504457 |
At 20% discount rate the NPV is negative (9504457 - 10011556 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Genomic Dx to discount cash flow at lower discount rates such as 15%.
Simplest Approach – If the investment project of Genomic Dx has a NPV value higher than Zero then finance managers at Genomic Dx can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.
In theory if the required rate of return or discount rate is chosen correctly by finance managers at Genomic Dx, then the stock price of the Genomic Dx should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.
In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.
Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Genomic Dx should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –
What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.
What can impact the cash flow of the project.
What will be a multi year spillover effect of various taxation regulations.
What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.
Understanding of risks involved in the project.
Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.
Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.
Stefanos Zenios, Robert Chess, Lyn Denend (2018), "Genomic Health: Launching a Paradigm Shift...and an Innovative New Test Harvard Business Review Case Study. Published by HBR Publications.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Genomic Health: Launching a Paradigm Shift...and an Innovative New Test
Services , Retail (Grocery)
Consumer/Non-Cyclical , Crops
Technology , Semiconductors
Energy , Oil & Gas Operations
Services , Motion Pictures
Healthcare , Biotechnology & Drugs
Technology , Scientific & Technical Instr.
Consumer/Non-Cyclical , Food Processing
Basic Materials , Chemical Manufacturing
Technology , Software & Programming
Technology , Software & Programming